Eupraxia Pharmaceuticals (EPRX) Invested Capital (2022 - 2023)
Eupraxia Pharmaceuticals' (EPRX) quarterly Invested Capital came in at $10.3 million in Q4 2023, up 12914.69% year-on-year from N/an in Q4 2022, and up 12914.69% on a QoQ basis from $79418.0 in Q4 2022.
Eupraxia Pharmaceuticals (EPRX) Invested Capital (2022 - 2023) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 2 years of Invested Capital data on file, last reported at $10.3 million in Q4 2023.
- On a quarterly basis, Invested Capital rose 12914.69% year-over-year to $10.3 million in Q4 2023; TTM through Sep 2024 was $10.3 million, a 12914.69% increase from a year earlier, with the FY2023 full-year figure at $10.3 million, up 12914.69% from the prior year.
- Invested Capital for Q4 2023 stood at $10.3 million, up from $79418.0 in the prior quarter.
- Over the last five years, Invested Capital for EPRX reached as high as $10.3 million in Q4 2023 and fell as low as $79418.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | Eupraxia Pharmaceuticals | 347.65 Mn | 347.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 10.34 Mn |
| Dec 31, 2022 | 79,418.00 |